NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 21/100

NeuBase Therapeutics Inc Myotonic Dystrophy Type 1 Data Webinar Transcript

Dec 16, 2020 / 01:00PM GMT
Release Date Price: $181.4 (+12.67%)
Dan Ferry
LifeSci Advisors, LLC - Moderator

Good morning, and thank you for joining us for today's call to discuss NeuBase's preclinical data for the company's myotonic dystrophy program. (Conference Instructions) As a reminder, this webinar is being recorded and a replay will be made available on the NeuBase website following the event.

I would now like to turn the call over to your host, Dietrich Stephan, Ph.D., Chief Executive Officer at NeuBase. Please go ahead, Dietrich.

Dietrich Stephan
NeuBase Therapeutics, Inc. - CEO, Founder, & Director

Thanks, Dan. Good morning, my name is Dietrich Stephan, the Chairman and CEO of NeuBase Therapeutics. Today, I'm proud to present a data package that is a culmination of the hard work of a simply amazing team here at NeuBase. I'm happy to represent this team's work today.

Joining me on the line is a senior management team of NeuBase: Sam Backenroth, our CFO; Dr. Bill Mann, our COO; and Dr. Curt Bradshaw, our CSO and newest team member. All of us will be available to answer questions after the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot